文献速递神经介入DSA

颅内动脉瘤Pipeline栓塞治疗后他汀类药物使用与血管造影及临床结局缺乏关联

Lack of Association between Statin Use and Angiographic and Clinical Outcomes after Pipeline Embolization for Intracranial Aneurysms.
PubMed 文献 · AJNR Am J Neuroradiol · 2017-02-02

该研究汇总3项Pipeline Embolization Device研究的1092例患者1221个动脉瘤数据,比较围手术期使用他汀(226例)与未使用他汀(866例)患者的长期血管造影和临床结局。结果显示两组在各时间点完全闭塞率及并发症率均无差异,他汀使用与血管造影或临床结局无关联。

要点

  • 他汀使用组与未使用组1年完全闭塞率82.8% vs 86.4%(P=.759),无显著差异。
  • 5年完全闭塞率他汀组93.3% vs 未使用组95.7%(P=1.000),无显著差异。
  • 主要并发症和神经性死亡率他汀组7.5% vs 未使用组7.1%(P=.77),无显著差异。

核心结论

  • 在Pipeline Embolization Device治疗的患者中,他汀使用与血管造影或临床结局无关联。

研究设计与样本

  • 对3项Pipeline Embolization Device研究(国际回顾性研究、Pipeline for Uncoilable or Failed Aneurysms研究、观察性注册研究)的汇总患者水平数据进行事后分析,共1092例患者1221个动脉瘤。

诊断标准与关键数值

  • 完全闭塞率:他汀组1年82.8%(24/29)vs 未使用组86.4%(70/81),P=.759。
  • 完全闭塞率:他汀组5年93.3%(14/15)vs 未使用组95.7%(45/47),P=1.000。
  • 主要并发症和神经性死亡率:他汀组7.5% vs 未使用组7.1%,P=.77。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Use of statin medications has been demonstrated to improve clinical and angiographic outcomes in patients receiving endovascular stent placement for coronary, peripheral, carotid, and intracranial stenoses. We studied the impact of statin use on long-term angiographic and clinical outcomes after flow-diverter treatment of intracranial aneurysms.

MATERIALS AND METHODS: We performed a post hoc analysis from pooled patient-level datasets from 3 Pipeline Embolization Device studies: the International Retrospective Study of the Pipeline Embolization Device, the Pipeline for Uncoilable or Failed Aneurysms Study, and the Aneurysm Study of Pipeline in an Observational Registry. We analyzed data comparing 2 subgroups: 1) patients on statin medication, and 2) patients not on statin medication at the time of the procedure and follow-up. Angiographic and clinical outcomes were compared by using the χ2 test, Fisher exact test, or Wilcoxon rank sum test.

RESULTS: We studied 1092 patients with 1221 aneurysms. At baseline, 226 patients were on statin medications and 866 patients were not on statin medications. The mean length of clinical and angiographic follow-up was 22.1 ± 15.1 months and 28.3 ± 23.7 months, respectively. There were no differences observed in angiographic outcomes at any time point between groups. Rates of complete occlusion were 82.8% (24/29) versus 86.4% (70/81) at 1-year (P = .759) and 93.3% (14/15) versus 95.7% (45/47) at 5-year (P = 1.000) follow-up for statin-versus-nonstatin-use groups, respectively. There were no differences in any complication rates between groups, including major morbidity and neurologic mortality (7.5% versus 7.1%, P = .77).

CONCLUSIONS: Our study found no association between statin use and angiographic or clinical outcomes among patients treated with the Pipeline Embolization Device.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Brinjikji W, Cloft H, Cekirge S, et al. Lack of Association between Statin Use and Angiographic and Clinical Outcomes after Pipeline Embolization for Intracranial Aneurysms. AJNR Am J Neuroradiol. 2017. PMID: 28154128. doi:10.3174/ajnr.A5078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。